Header Logo

Connection

KAREN H LU to Aged

Back to Details
This is a "connection" page, showing publications KAREN H LU has written about Aged.
KAREN H LU
Connection Strength
1.072
Aged
  1. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 11 01; 9(11):1547-1555.
    View in: PubMed
    Score: 0.037
  2. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. 2017 08; 146(2):399-404.
    View in: PubMed
    Score: 0.024
  3. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 08; 146(2):234-239.
    View in: PubMed
    Score: 0.023
  4. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res. 2017 Jul 15; 23(14):3628-3637.
    View in: PubMed
    Score: 0.023
  5. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
    View in: PubMed
    Score: 0.022
  6. Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. Obstet Gynecol. 2016 08; 128(2):357-363.
    View in: PubMed
    Score: 0.022
  7. Is it all Lynch syndrome?: An assessment of family history in individuals with mismatch repair-deficient tumors. Genet Med. 2015 Jun; 17(6):476-84.
    View in: PubMed
    Score: 0.020
  8. Response to an exercise intervention after endometrial cancer: differences between obese and non-obese survivors. Gynecol Oncol. 2014 Apr; 133(1):48-55.
    View in: PubMed
    Score: 0.019
  9. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol. 2014 Apr 20; 32(12):1249-55.
    View in: PubMed
    Score: 0.019
  10. Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist. Gynecol Oncol. 2013 Dec; 131(3):619-23.
    View in: PubMed
    Score: 0.018
  11. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 Oct 01; 119(19):3454-61.
    View in: PubMed
    Score: 0.018
  12. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila). 2011 Sep; 4(9):1401-8.
    View in: PubMed
    Score: 0.016
  13. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol. 2011 Apr; 204(4):355.e1-7.
    View in: PubMed
    Score: 0.015
  14. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res. 2010 Dec 01; 70(23):9765-76.
    View in: PubMed
    Score: 0.015
  15. Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. Am J Obstet Gynecol. 2011 Feb; 204(2):167.e1-5.
    View in: PubMed
    Score: 0.015
  16. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010 May; 115(5):945-952.
    View in: PubMed
    Score: 0.014
  17. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women. Obstet Gynecol. 2008 Jul; 112(1):56-63.
    View in: PubMed
    Score: 0.013
  18. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008 Aug; 110(2):196-201.
    View in: PubMed
    Score: 0.013
  19. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. Int J Gynecol Cancer. 2008 Jan-Feb; 18(1):146-51.
    View in: PubMed
    Score: 0.012
  20. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
    View in: PubMed
    Score: 0.011
  21. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006 Jun 01; 106(11):2376-81.
    View in: PubMed
    Score: 0.011
  22. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005 Dec 20; 23(36):9344-50.
    View in: PubMed
    Score: 0.011
  23. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005 Sep 01; 11(17):6116-26.
    View in: PubMed
    Score: 0.010
  24. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer. 2005 May-Jun; 15(3):510-6.
    View in: PubMed
    Score: 0.010
  25. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005 Mar; 105(3):569-74.
    View in: PubMed
    Score: 0.010
  26. Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion. Clin Cancer Res. 2024 Nov 15; 30(22):5073-5082.
    View in: PubMed
    Score: 0.010
  27. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. J Natl Cancer Inst. 2024 Nov 01; 116(11):1798-1806.
    View in: PubMed
    Score: 0.010
  28. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 01; 22(15):3126-32.
    View in: PubMed
    Score: 0.010
  29. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 2004 Aug; 104(2):255-60.
    View in: PubMed
    Score: 0.010
  30. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004 Aug; 94(2):456-62.
    View in: PubMed
    Score: 0.010
  31. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clin Cancer Res. 2024 Jul 15; 30(14):2986-2995.
    View in: PubMed
    Score: 0.010
  32. Delivery of hereditary cancer genetics services to patients newly diagnosed with ovarian and endometrial cancers at three gynecologic oncology clinics in the USA, Brazil, and Mexico. Int J Gynecol Cancer. 2024 Jul 01; 34(7):1020-1026.
    View in: PubMed
    Score: 0.010
  33. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004 May; 13(5):748-52.
    View in: PubMed
    Score: 0.009
  34. Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol. 2024 06; 185:101-107.
    View in: PubMed
    Score: 0.009
  35. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003 Dec; 91(3):463-9.
    View in: PubMed
    Score: 0.009
  36. beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol. 2003 Mar; 88(3):363-8.
    View in: PubMed
    Score: 0.009
  37. Impact of a tiered discharge opioid algorithm on prescriptions and patient-reported outcomes after open gynecologic surgery. Int J Gynecol Cancer. 2021 07; 31(7):1052-1060.
    View in: PubMed
    Score: 0.008
  38. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31.
    View in: PubMed
    Score: 0.008
  39. Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells. Sci Rep. 2021 04 28; 11(1):9149.
    View in: PubMed
    Score: 0.008
  40. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2021 06; 161(3):660-667.
    View in: PubMed
    Score: 0.008
  41. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
    View in: PubMed
    Score: 0.008
  42. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2020 12; 29(12):2504-2512.
    View in: PubMed
    Score: 0.007
  43. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer. 2020 11; 30(11):1733-1737.
    View in: PubMed
    Score: 0.007
  44. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.007
  45. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020 08; 30(8):1195-1202.
    View in: PubMed
    Score: 0.007
  46. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000 Jul; 18(14):2728-32.
    View in: PubMed
    Score: 0.007
  47. Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2020 04; 30(4):485-490.
    View in: PubMed
    Score: 0.007
  48. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer. 2020 02 15; 126(4):725-736.
    View in: PubMed
    Score: 0.007
  49. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 02 01; 26(3):581-587.
    View in: PubMed
    Score: 0.007
  50. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer. 2019 10 01; 125(19):3347-3353.
    View in: PubMed
    Score: 0.007
  51. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28.
    View in: PubMed
    Score: 0.007
  52. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prev Res (Phila). 2019 06; 12(6):391-400.
    View in: PubMed
    Score: 0.007
  53. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 08; 221(2):136.e1-136.e9.
    View in: PubMed
    Score: 0.007
  54. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. Obstet Gynecol. 2019 04; 133(4):795-802.
    View in: PubMed
    Score: 0.007
  55. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol. 2019 03; 152(3):439-444.
    View in: PubMed
    Score: 0.007
  56. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol. 2019 03; 152(3):501-508.
    View in: PubMed
    Score: 0.007
  57. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. Gynecol Oncol. 2019 02; 152(2):328-333.
    View in: PubMed
    Score: 0.007
  58. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 01; 152(1):31-37.
    View in: PubMed
    Score: 0.006
  59. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018 11; 151(2):269-274.
    View in: PubMed
    Score: 0.006
  60. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
    View in: PubMed
    Score: 0.006
  61. Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes. Obstet Gynecol. 2018 08; 132(2):281-290.
    View in: PubMed
    Score: 0.006
  62. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 07; 132(1):52-58.
    View in: PubMed
    Score: 0.006
  63. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018 09; 150(3):451-459.
    View in: PubMed
    Score: 0.006
  64. KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. Nat Commun. 2018 06 27; 9(1):2496.
    View in: PubMed
    Score: 0.006
  65. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res. 1998 Jun 01; 58(11):2328-30.
    View in: PubMed
    Score: 0.006
  66. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. Br J Cancer. 2018 04; 118(8):1123-1129.
    View in: PubMed
    Score: 0.006
  67. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
    View in: PubMed
    Score: 0.006
  68. Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer. 2018 02; 28(2):285-292.
    View in: PubMed
    Score: 0.006
  69. Endometrial cancer survivors' sleep patterns before and after a physical activity intervention: A retrospective cohort analysis. Gynecol Oncol. 2018 04; 149(1):133-139.
    View in: PubMed
    Score: 0.006
  70. Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. Int J Gynecol Cancer. 2018 01; 28(1):114-121.
    View in: PubMed
    Score: 0.006
  71. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
    View in: PubMed
    Score: 0.006
  72. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5912-5922.
    View in: PubMed
    Score: 0.006
  73. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer. 2017 Sep 01; 123(17):3261-3268.
    View in: PubMed
    Score: 0.006
  74. Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33.
    View in: PubMed
    Score: 0.006
  75. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clin Cancer Res. 2017 Aug 01; 23(15):4473-4481.
    View in: PubMed
    Score: 0.006
  76. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111.
    View in: PubMed
    Score: 0.006
  77. A comparison between Lynch syndrome and sporadic colorectal cancer survivors' satisfaction with their healthcare providers. Cancer Med. 2017 03; 6(3):698-707.
    View in: PubMed
    Score: 0.006
  78. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget. 2016 10 25; 7(43):69097-69110.
    View in: PubMed
    Score: 0.006
  79. Sexual health of endometrial cancer survivors before and after a physical activity intervention: A retrospective cohort analysis. Gynecol Oncol. 2016 Dec; 143(3):589-595.
    View in: PubMed
    Score: 0.006
  80. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol. 2016 06; 45(3):884-95.
    View in: PubMed
    Score: 0.006
  81. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. Int J Gynecol Cancer. 2016 07; 26(6):1070-7.
    View in: PubMed
    Score: 0.006
  82. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
    View in: PubMed
    Score: 0.005
  83. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis. Int J Gynecol Cancer. 2016 May; 26(4):697-704.
    View in: PubMed
    Score: 0.005
  84. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7.
    View in: PubMed
    Score: 0.005
  85. Management for Elderly Women With Advanced-Stage, High-Grade Endometrial Cancer. Obstet Gynecol. 2015 Dec; 126(6):1198-1206.
    View in: PubMed
    Score: 0.005
  86. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.005
  87. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol. 2015 Dec; 39(8):689-97.
    View in: PubMed
    Score: 0.005
  88. Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: analysis of the National Cancer Database. Gynecol Oncol. 2015 Oct; 139(1):77-83.
    View in: PubMed
    Score: 0.005
  89. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis. Gynecol Oncol. 2015 Oct; 139(1):84-9.
    View in: PubMed
    Score: 0.005
  90. The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women. Cancer Epidemiol Biomarkers Prev. 2015 Sep; 24(9):1407-15.
    View in: PubMed
    Score: 0.005
  91. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20; 33(24):2675-82.
    View in: PubMed
    Score: 0.005
  92. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015 Oct; 139(1):40-6.
    View in: PubMed
    Score: 0.005
  93. Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients. Gynecol Oncol. 2015 Mar; 136(3):440-5.
    View in: PubMed
    Score: 0.005
  94. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10; 33(8):930-6.
    View in: PubMed
    Score: 0.005
  95. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79.
    View in: PubMed
    Score: 0.005
  96. Combined colonoscopy and endometrial biopsy cancer screening results in women with Lynch syndrome. Gynecol Oncol. 2014 Oct; 135(1):85-9.
    View in: PubMed
    Score: 0.005
  97. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome. Gynecol Oncol. 2014 Aug; 134(2):319-25.
    View in: PubMed
    Score: 0.005
  98. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer. 2014 Jun; 13(2):291-9.
    View in: PubMed
    Score: 0.005
  99. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55.
    View in: PubMed
    Score: 0.005
  100. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila). 2014 Jul; 7(7):686-97.
    View in: PubMed
    Score: 0.005
  101. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55.
    View in: PubMed
    Score: 0.005
  102. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol. 2014 Mar 10; 32(8):824-9.
    View in: PubMed
    Score: 0.005
  103. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des. 2014; 20(11):1655-63.
    View in: PubMed
    Score: 0.005
  104. Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome. Mol Carcinog. 2015 Jun; 54(6):430-9.
    View in: PubMed
    Score: 0.005
  105. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014 Mar; 210(3):257.e1-6.
    View in: PubMed
    Score: 0.005
  106. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
    View in: PubMed
    Score: 0.004
  107. Genotype in BRCA-associated breast cancers. Breast J. 2013 Jan-Feb; 19(1):87-91.
    View in: PubMed
    Score: 0.004
  108. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012 Nov 06; 107(10):1776-82.
    View in: PubMed
    Score: 0.004
  109. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82.
    View in: PubMed
    Score: 0.004
  110. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012 Apr; 206(4):351.e1-8.
    View in: PubMed
    Score: 0.004
  111. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012 Apr; 206(4):349.e1-7.
    View in: PubMed
    Score: 0.004
  112. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol. 2012 Mar; 138(3):377-85.
    View in: PubMed
    Score: 0.004
  113. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
    View in: PubMed
    Score: 0.004
  114. Genetic variants in TGF-? pathway are associated with ovarian cancer risk. PLoS One. 2011; 6(9):e25559.
    View in: PubMed
    Score: 0.004
  115. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012 Jan 15; 118(2):321-5.
    View in: PubMed
    Score: 0.004
  116. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer. 2012 Jan 01; 118(1):91-100.
    View in: PubMed
    Score: 0.004
  117. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011 Mar; 4(3):365-74.
    View in: PubMed
    Score: 0.004
  118. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011 Mar; 4(3):375-83.
    View in: PubMed
    Score: 0.004
  119. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J. 2011 Mar-Apr; 17(2):210-2.
    View in: PubMed
    Score: 0.004
  120. Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. J Exp Clin Cancer Res. 2011 Jan 07; 30:5.
    View in: PubMed
    Score: 0.004
  121. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
    View in: PubMed
    Score: 0.004
  122. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
    View in: PubMed
    Score: 0.004
  123. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010 Aug 01; 28(22):3570-6.
    View in: PubMed
    Score: 0.004
  124. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24; 376(9737):245-51.
    View in: PubMed
    Score: 0.004
  125. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010 May 01; 28(13):2159-66.
    View in: PubMed
    Score: 0.004
  126. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72.
    View in: PubMed
    Score: 0.004
  127. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther. 2009 Nov; 8(22):2126-35.
    View in: PubMed
    Score: 0.003
  128. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009 Oct; 115(1):6-11.
    View in: PubMed
    Score: 0.003
  129. Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol. 2009 Sep; 46(15):3037-49.
    View in: PubMed
    Score: 0.003
  130. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer. 2009 Feb 15; 115(4):725-30.
    View in: PubMed
    Score: 0.003
  131. Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol. 2009 Mar; 200(3):288.e1-8.
    View in: PubMed
    Score: 0.003
  132. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer. 2008 Apr 14; 8:101.
    View in: PubMed
    Score: 0.003
  133. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol. 2007 Oct 10; 25(29):4635-41.
    View in: PubMed
    Score: 0.003
  134. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res. 2007 Aug 15; 13(16):4800-6.
    View in: PubMed
    Score: 0.003
  135. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol. 2007 Oct; 107(1):58-65.
    View in: PubMed
    Score: 0.003
  136. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007 Jun; 105(3):625-9.
    View in: PubMed
    Score: 0.003
  137. Paclitacxel and carboplatin in advanced non-small-cell lung cancer. Biomed Pharmacother. 2006 Dec; 60(10):698-700.
    View in: PubMed
    Score: 0.003
  138. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
    View in: PubMed
    Score: 0.003
  139. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4968-76.
    View in: PubMed
    Score: 0.003
  140. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005 Mar 15; 11(6):2149-55.
    View in: PubMed
    Score: 0.003
  141. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res. 2004 Oct 01; 10(19):6559-66.
    View in: PubMed
    Score: 0.002
  142. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004 Apr; 28(4):496-504.
    View in: PubMed
    Score: 0.002
  143. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol. 2002 Sep; 26(9):1129-41.
    View in: PubMed
    Score: 0.002
  144. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol. 2002 Jan; 99(1):3-10.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.